Table 2.

Characteristics of all chronic subdural hematoma patients and treatment subgroups

	Total sample n = 1133		Non-operative treatment n = 168		Operative treatment n = 965		p value
	n	%	n	%	n	%
Median age, years, IQR	76	67–83	79	68–86	76	66–82	0.001
Sex
Men	736	65.0	102	60.7	634	65.7	0.21
Traumatic etiology	672	59.3	107	63.7	565	58.5	0.21
Comorbidity
Cardiovascular disease	644	56.8	96	57.1	548	56.8	0.93
Diabetes	178	15.7	27	16.1	151	15.6	0.89
Chronic alcohol abuse	126	11.1	20	11.9	106	11.0	0.73
Cerebrovascular disease	124	10.9	24	14.3	100	10.4	0.13
Dementia	99	8.8	26	15.7	73	7.6	0.001
Pulmonary disease	68	6.0	16	9.5	52	5.4	0.05
Epilepsy	32	2.8	3	1.8	29	3.0	0.38
Neurodegenerative disease	20	1.8	7	4.2	13	1.3	0.01
Hydrocephalus	9	0.8	0	0	9	0.9	0.21
Medication
Antiplatelet	268	23.7	36	21.4	232	24.0	0.46
Warfarin	187	16.5	26	15.5	161	16.7	0.69
Warfarin AND antiplatelet	23	2.0	2	1.2	21	2.2	0.40
Admission GCS
13–15	1007	88.9	157	93.5	850	88.1	0.04
9–12	91	8.0	8	4.8	83	8.6	0.91
3–8	35	3.1	3	1.8	32	3.3	0.29
Admission mRS 0–3	580	51.2	121	72.0	459	47.6	< 0.001
Symptoms
Hemiparesis	444	39.2	9	5.4	435	45.1	< 0.001
Vertigo or postural instability	408	36.0	35	20.8	373	38.7	< 0.001
Disorientation/memory impairment	390	34.4	54	32.1	336	34.8	0.50
General malaise	367	32.4	50	29.8	317	32.8	0.43
Headache	340	30.0	28	16.7	312	32.3	< 0.001
Aphasia	245	21.6	9	5.4	236	24.5	< 0.001
Seizure	117	10.3	28	16.7	89	9.2	0.003
Nausea and/or vomiting	60	5.3	7	4.2	53	5.5	0.48

IQR Interquartile range; GCS Glasgow Coma Scale; mRS Modified Rankin Scale